he FDA’s decision on Friday to approve a new blood thinner from Portola Pharmaceuticals has biotech investors optimistic that the agency, now under new management, will be easier to get along with than administrations past.

Portola’s drug, called Bevyxxa, overcame what could have been a damning clinical result — it failed to show statistically significant benefits over an old generic. It’s now approved to prevent blood clots in patients who’ve been hospitalized for medical illness but didn’t require surgery.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.